Molecular Subtype
Myeloproliferative Neoplasm, BCR-ABL1 Negative
CI-CAN-00003386Explore in graph →
Hematologic94 active trials2 approved drugs8 evidence items
- NCIt
- C198555
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00003386Explore in graph →
Clinical trials
333 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (56)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06397313 | RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis(POTAMI-61) | terminated | Phase 2 | 36 | Ryvu Therapeutics SAINDUSTRY | 2 | Sep 16, 2026 | clinicaltrials |
| NCT05853458 | Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors(HU-F-AIM) | terminated | Phase 4 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 18, 2026 |
| clinicaltrials |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | terminated | N/A | 200 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03878199 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | terminated | Phase 1 / Phase 2 | 12 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | terminated | Phase 3 | 252 | Incyte CorporationINDUSTRY | 17 | Oct 21, 2025 | clinicaltrials |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | terminated | Phase 3 | 177 | Incyte CorporationINDUSTRY | 19 | Oct 2, 2025 | clinicaltrials |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | terminated | Phase 2 | 31 | Roswell Park Cancer InstituteOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT01688011 | Connect® Myeloid Disease Registry | terminated | — | 2,013 | CelgeneINDUSTRY | 2 | Jul 3, 2025 | clinicaltrials |
| NCT00522990 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | terminated | Phase 1 / Phase 2 | 48 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03972943 | CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia | terminated | Early Phase 1 | 8 | University of UtahOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 51 | Asana BioSciencesINDUSTRY | 2 | Jun 7, 2023 | clinicaltrials |
| NCT04866056 | Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. | terminated | Phase 1 / Phase 2 | 1 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT01014546 | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | terminated | Phase 1 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT03303950 | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03287245 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera | terminated | Phase 2 | 27 | Hoffmann-La RocheINDUSTRY | 4 | Dec 8, 2021 | clinicaltrials |
| NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia(PAC326) | terminated | Phase 3 | 311 | CTI BioPharmaINDUSTRY | 12 | Nov 18, 2021 | clinicaltrials |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | terminated | Phase 1 | 20 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | terminated | Phase 3 | 327 | CTI BioPharmaINDUSTRY | 12 | Sep 29, 2020 | clinicaltrials |
| NCT01038856 | Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera(OSI-TAR-766) | terminated | Phase 2 | 5 | University of OklahomaOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT03121599 | 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms | terminated | N/A | 3 | Hamad Medical CorporationINDUSTRY | 1 | Aug 11, 2020 | clinicaltrials |
| NCT02730884 | Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT03718143 | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis | terminated | Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT01998828 | Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia | terminated | Phase 2 | 39 | Sierra Oncology LLC - a GSK companyINDUSTRY | 5 | Apr 20, 2020 | clinicaltrials |
| NCT02435550 | iCare for Cancer Patients | terminated | N/A | 136 | University of FloridaOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | terminated | Phase 2 | 4 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02421354 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | terminated | Phase 2 | 5 | Emory UniversityOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias(POE07-01) | terminated | Phase 1 | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 15, 2018 | clinicaltrials |
| NCT00538980 | Dasatinib in Polycythemia Vera | terminated | Phase 2 | 10 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT00595829 | A Phase 1 Study of XL019 in Adults With Polycythemia Vera | terminated | Phase 1 | 3 | ExelixisINDUSTRY | 1 | Aug 21, 2015 | clinicaltrials |
| NCT01291784 | Anti-TGF-beta Therapy in Patients With Myelofibrosis | terminated | Phase 1 | 3 | John MascarenhasOTHER | 1 | Dec 8, 2014 | clinicaltrials |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | terminated | N/A | 10 | Indiana UniversityOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00393380 | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor | terminated | Phase 2 | 13 | The Emmes Company, LLCINDUSTRY | 1 | Apr 29, 2013 | clinicaltrials |
| NCT01645124 | Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)(CYTO-PV) | terminated | Phase 3 | 365 | Consorzio Mario Negri SudOTHER | 1 | Jul 20, 2012 | clinicaltrials |
| NCT00522574 | A Safety Study of XL019 in Adults With Myelofibrosis | terminated | Phase 1 | 100 | ExelixisINDUSTRY | 1 | Apr 5, 2011 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials